Hospira voluntarily recalled lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection and lot EG8933 of 1% Lidocaine HCl Injection, due to mislabeling whereby a portion of each lot was incorrectly labeled as the other product. Both drugs are indicated for the production of local or regional anesthesia. Using lidocaine 1% instead of bupivacaine 0.5% drug instead could lead to underdose and inadequate pain management, while use of bupivacaine 0.5% instead of lidocaine 1% could lead to overdose, which could cause seizures, respiratory abnormalities, and heart problems.
